Company profile: Proteomedix
1.1 - Company Overview
Company description
- Provider of blood-based prostate cancer diagnostics, notably Proclarix: a test panel that integrates biomarkers and patient data to compute a risk score for high-grade prostate cancer using samples taken for PSA testing. Clinical evidence from 955 subjects shows Proclarix reduces unnecessary biopsies by accurately detecting clinically significant cancer; offers biomarker signatures for diagnosis, prognosis, and therapy management.
Products and services
- Proclarix: Blood-based prostate cancer test panel using PSA-drawn samples, integrating novel biomarker signatures and patient data to calculate a risk score for high-grade disease
- Proclarix Risk Score: Algorithmic cumulative score derived from biomarker signatures and patient data within Proclarix, quantifying the likelihood of high‑grade prostate cancer to support accurate risk stratification
- Clinical Evidence for Proclarix: Retrospective-validated analysis of 955 subjects showing Proclarix accurately detects clinically significant prostate cancer and reduces the number of unnecessary biopsies.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Proteomedix
Immedica
HQ: Sweden
Website
- Description: Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immedica company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
Highlight Therapeutics
HQ: Spain
Website
- Description: Provider of an RNA-based immuno-oncology therapy, BO-112, designed to initiate an immune response against 'cold' tumors, making them 'hot' and visible to the immune system. Services include clinical development and trials (successful Phase 1 monotherapy, Phase 1b with anti-PD1), collaborations with Merck & Co and UCLA, and R&D into BO-112’s mechanism where checkpoint inhibitors are ineffective.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Highlight Therapeutics company profile →
Fusion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fusion Pharmaceuticals company profile →
GamaMabs
HQ: France
Website
- Description: Provider of optimized monoclonal antibody therapeutics for cancer, developing clinical-stage immuno-oncology candidates including GM102 (formerly 3C23K), a mAb targeting the anti-Müllerian hormone receptor (AMHR2) in gynecological cancers, currently in phase Ia/Ib.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GamaMabs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Proteomedix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Proteomedix
2.2 - Growth funds investing in similar companies to Proteomedix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Proteomedix
4.2 - Public trading comparable groups for Proteomedix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →